Preservation by vaporization

• US 9,469,835 B2
• Filed: 06/01/2005
• Issued: 10/18/2016
• Est. Priority Date: 06/02/2004
• Status: Active Grant

• Current Assignee: Universal Stabilization Technologies, Inc.
• Original Assignee: Universal Stabilization Technologies, Inc.
• Inventors: Bronshtein, Victor
• Primary Examiner(s): Landau, Sharmila G.
• Assistant Examiner(s): MACAULEY, SHERIDAN R
• Application Number:
  US11/569,342
• Publication Number:
  US 20080229609A1
• Time in Patent Office: 4,157 Days
• Field of Search: 435/2
• US Class Current: 1/1
• CPC Class Codes: A01N 1/0284 Temperature processes, i.e. using a designated change in temperature over time
• CPC Class Codes: C12N 1/04 Preserving or maintaining viable microorganisms immobilised microorganisms C12N11/00
• CPC Class Codes: C12N 9/0006 acting on CH-OH groups as donors (1.1)
• CPC Class Codes: C12N 9/96 Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Abstract

Significant research is being done to develop and improve delivery mechanisms for biopharmaceuticals and vaccines, including pulmonary (inhalation), nasal, transdermal, and oral alternatives. Market projections indicate that the delivery of proteins and vaccines by inhalation and oral formulation has become and will continue to be increasingly important. These delivery mechanisms, to be effective, will require better stabilization of the biologicals so that they can maintain potency and effectiveness at ambient temperatures for extended periods of time. The novel Preservation by Vaporization (PBV) Technology described herein provides cost-effective and efficient industrial scale stabilization of proteins, viruses, bacteria, and other sensitive biologicals, thereby allowing a production of products that are not possible to be produced by existing methods. The suggested new PBV process comprises primary drying under vacuum from a partially frozen state (i.e. slush) at near subzero temperatures followed by stability drying at elevated temperatures (i.e., above 40 degrees Celsius). The new suggested method can be performed aseptically in unit doze format (in vials) and/or in bulk format (in trays, bags, or other containers). The drying can be performed as a continuous load process in a manifold vacuum dryer comprising a plurality (e.g., 30) of vacuum chambers attached to a condenser during the drying.

Claims

1. A method for preserving one or more therapeutically active biologicals, comprising:

partially freezing a suspension comprising;

one or more therapeutically active biologicals;

one or more protective excipients; and

an aqueous solution

by cooling to a temperature above −

20°

C. to obtain a slush comprising a mixture of ice crystals and a liquid between the ice crystals;

performing primary drying of the slush under conditions to prevent or inhibit splattering of the liquid to provide a mechanically stable foam optionally comprising a skim of a thin freeze-dried cake;

wherein the conditions comprise applying temperatures above −

20°

C. and a vacuum pressure below 3 Torr so the liquid boils and the ice crystals sublime; and

performing secondary drying by desorbing water from the mechanically stable foam under high vacuum at ambient temperature or above to increase the foam'"'"'s glass transition temperature to provide preserved therapeutically active biologicals in a glassy matrix that is stable at ambient temperatures; and

wherein the biologicals are not subjected to temperatures equal to T_g′

or below, wherein T_g′

is the temperature at which the suspension completely solidifies during cooling.

2. The method according to claim 1, wherein the one or more therapeutically active biologicals comprises blood, blood components, animal cells loaded with nonreducing disaccharides, nonreducing derivatives of monosaccharides, arbutin, or amino acids.

3. The method of claim 1, wherein the one or more therapeutically active biologicals is selected from the group consisting of peptides, proteins, nucleic acids, antibodies, vaccines, bacteria, viruses, liposomes, platelets and other blood components, and mammalian cell suspensions.

4. The method of claim 1, wherein at least one of the one or more therapeutically active biologicals is an attenuated viral vaccine comprising live viruses selected from the group consisting of influenza virus, parainfluenza virus, AAV, adenovirus, respiratory syncytial virus, herpes simplex virus, cytomegalovirus, SARS virus, corona virus family members, human metapneumovirus, and Epstein-Barr virus, measles, mumps, and rubella.

5. The method according to claim 1, wherein the one or more protective excipients comprises a nonreducing monosaccharide, sugar alcohol, oligosaccharide, amino acid, polyvinylpyrrolodone, polyethylene glycol, Ficol, Inulin, albumin, gelatin, whey proteins, and/or a polaxomer.

6. The method of claim 1, wherein the one or more therapeutically active biologicals in a glassy matrix has a moisture content from about 0.01% to about 2%.

7. The method of claim 1, wherein the conditions of primary drying comprise a temperature of at least 10°

C. higher than T_g′

.

8. The method of claim 1, wherein the conditions of primary drying comprise a temperature of −

15°

C. or higher.

9. The method of claim 1, wherein the conditions of primary drying comprise a temperature of −

10°

C. or higher.

10. The method of claim 1, wherein the conditions of primary drying comprise a temperature of −

5°

C. or higher.

11. The method of claim 1, wherein performing secondary drying further comprises applying a temperature of 37°

C. or higher.

12. The method of claim 1, wherein the one or more therapeutically active biologicals are mechanically stable at ambient temperature without vacuum.

13. The method of claim 1, further comprising reconstituting the one or more therapeutically active biologicals in water, wherein the one or more therapeutically active biologicals do not lose biological activity.

14. The method of claim 1, wherein providing the biological suspension further comprises encapsulating the one or more therapeutically active biologicals as a hydrogel.

15. A scalable method for preserving one or more therapeutically active biologicals, comprising:

partially freezing a suspension comprising;

one or more therapeutically active biologicals;

one or more protective excipients; and

an aqueous solution

by cooling to a temperature higher than −

20°

C. to obtain a slush comprising a mixture of ice crystals and liquid between the crystals;

performing primary drying of the slush under conditions to prevent or inhibit splattering of the liquid to provide a mechanically stable foam;

wherein the conditions comprise applying a temperature above −

20°

C. and a vacuum pressure below 3 Torr so the liquid boils and the ice crystals sublime; and

performing secondary drying of the mechanically stable foam under high vacuum at ambient temperature; and

continuing the secondary drying at temperatures greater than 40°

C. to provide preserved therapeutically active biologicals in a glassy matrix that is stable at ambient temperatures for long term storage; and

wherein the biologicals are not subjected to temperatures equal to T_g′

or below, wherein T_g′

is the temperature at which the suspension completely solidifies during cooling.

16. The method according to claim 15, wherein the one or more therapeutically active biologicals comprises blood, blood components, animal cells loaded with nonreducing disaccharides, nonreducing derivatives of monosaccharides, arbutin, or amino acids.

17. The method of claim 15, wherein the one or more therapeutically active biologicals is selected from the group consisting of peptides, proteins, nucleic acids, antibodies, vaccines, bacteria, viruses, liposomes, platelets and other blood components, and mammalian cell suspensions.

18. The method of claim 15, wherein at least one of the one or more therapeutically active biologicals is an attenuated viral vaccine comprising live viruses selected from the group consisting of influenza virus, parainfluenza virus, AAV, adenovirus, respiratory syncytial virus, herpes simplex virus, cytomegalovirus, SARS virus, corona virus family members, human metapneumovirus, and Epstein-Barr virus, measles, mumps, and rubella.

19. The method according to claim 15, wherein the one or more protective excipients comprises a nonreducing monosaccharide, sugar alcohol, oligosaccharide, amino acid, polyvinylpyrrolodone, polyethylene glycol, Ficol, Inulin, albumin, gelatin, whey proteins, or a polaxomer.

20. The method of claim 15, wherein the one or more therapeutically active biologicals has a moisture content from about 0.01% to about 2%.

21. The method of claim 15, wherein primary drying comprises applying a vacuum pressure of about 1 to 3 Torr.

22. The method of claim 15, wherein primary drying comprises a temperature of at least 10°

C. higher than T_g′

.

23. The method of claim 15, wherein primary drying comprises a temperature of −

15°

C. or higher.

24. The method of claim 15, wherein primary drying comprises a temperature of −

10°

C. or higher.

25. The method of claim 15, wherein primary drying comprises a temperature of −

5°

C. or higher.